ArticleDiscover oncology2025
Therapeutic effect of Chelidonium majus hydro-alcoholic extract alone and in combination with oxaliplatin on ovarian cancer cell line.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer.Biomedicines · 2026Review
- Evaluating the mechanisms and therapeutic potential of ZnO nanoparticles as selective anticancer agents for lung malignancies.Discover nano · 2026Review
- Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance.Discover oncology · 2025Review
- Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the leading cause of tumor-related deaths among gynecologic cancers. Patients diagnosed with advanced stages of OC urgently require effective therapeutic interventions, but current therapies often fail in patients with recurrent platinum-resistant tumors. Previous research has shown the cytotoxic effects of Chelidonium majus (C. majus) extract on tumors. In this study we have investigated the effects of combined and independent effects of oxaliplatin and C. majus extract on ovarian cancer cell proliferation and apoptosis. Using the OVACR3 cell line as an in vitro model, we applied the MTT assay for cell growth assessment and RT-qPCR to measure caspase-3, β-catenin, and ZEB1 expression. The results demonstrated that both oxaliplatin and C. majus extract significantly inhibited cell growth and promoted apoptosis, with enhanced effects observed when used together. The inhibition of ZEB1 and β-catenin suggest their involvement in the observed anti-cancer effects. Treated groups also showed higher caspase-3 expression compared to controls. Our findings confirm the synergistic potential of combining oxaliplatin and C. majus extract in treating OC, possibly through the ZEB1/β-catenin pathway. Further research is needed to confirm the clinical applicability and underlying mechanisms of this treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.